TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04387604
Drug: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
Normalized name: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PRN regimen. Treatment Schedule Repeat injections at every 4-week visit if eye improves or worsens (defined as ≥5 letter change from last injection or ≥10% CST change on OCT from last injection or CSF\>300 μm at any timepoint).~Defer injections if either BCVA of 85 letters and OCT CSF normal (CSF≤300 μm and non-existent intra- or sub-retinal fluid); or OCT CSF normal (CSF≤300 μm) and stable BCVA (defined as \< 5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CSF normal and stable BCVA).~Resume injections if BCVA or OCT worsens.
Study: NCT00475657
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles
Study: NCT00475657
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, intravenous (IV), every 21 days x 6 cycles
Study: NCT02992743
Drug: letetresgene autoleucel (GSK3377794)
Normalized name: Brexucabtagene autoleucel
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion.
Study: NCT03641586
Drug: BGB-283
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02992743
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study: NCT02981446
Drug: DE-117
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
Study: NCT02981446
Drug: Latanoprost ophthalmic solution
Normalized name: Latanoprost Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
Study: NCT03636503
Drug: Utomilumab
Normalized name: Utomilumab
DrugBank: Utomilumab (DB15113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
Study: NCT00017108
Drug: chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03636503
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
Study: NCT00017108
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00761735
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
Study: NCT00381680
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00381680
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00381680
Drug: pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT00381680
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV
Study: NCT03944577
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
Study: NCT03852056
Drug: MFP Fluoride toothpaste
Normalized name: sodium fluoride Toothpaste [Fluoridex]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
Study: NCT03852056
Drug: Stannous fluoride toothpaste
Normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
Study: NCT02317471
Drug: Oxaliplatin+S-1
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles.
Study: NCT00381680
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00381680
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02222623
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
Study: NCT00391586
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient
Study: NCT00391586
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
Study: NCT00381680
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT04408326
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
Study: NCT04408326
Drug: Interleukin-1 receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
Study: NCT01428388
Drug: Intravitreal injection of bevacizumab
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg per dose, delivered monthly by intravitreal injection for six months
Study: NCT01428388
Drug: Intravitreal injection of ranibizumab (0.5 mg per dose)
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg per dose, delivered monthly by intravitreal injection for six months
Study: NCT01651156
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral taken
Study: NCT01012765
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
Study: NCT01012765
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
Study: NCT02598362
Drug: ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
Study: NCT04111913
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anlotinib once daily on days 1-14 of 21days cycle.
Study: NCT01143129
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose (1 mg/kg) at start of cardiac surgical procedure
Study: NCT00570492
Drug: Fluticasone furoate nasal spray
Normalized name: fluticasone furoate Metered Dose Nasal Spray
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray 110mg QD
Study: NCT00045565
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04202601
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.
Study: NCT00908375
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
Study: NCT00908375
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
Study: NCT01024894
Drug: Interleukin-7
Normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
Study: NCT00734188
Drug: PTI-6D2
Normalized name: PTI-110
DrugBank: PTI-110 (DB18298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monoclonal antibody
Study: NCT01484691
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
Study: NCT01621269
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01957995
Drug: nanosomal docetaxel lipid suspension
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03377608
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
Study: NCT03377608
Drug: Depo-Provera
Normalized name: Depo-Provera
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
Study: NCT01993290
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
Study: NCT01658436
Drug: BEZ235 (Stage 1)
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
Study: NCT00686712
Drug: 1- Insulin glargine QHS
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings \<120 mg/dL)
Study: NCT00686712
Drug: 2 - Insulin glargine QAM
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings \<120 mg/dL)
Study: NCT00686712
Drug: 3 - NPH insulin QHS
Normalized name: INSULIN,NPH,BEEF
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses \<120 mg/dL)
Study: NCT03093129
Drug: artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015).
Study: NCT00003401
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003401
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003401
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003401
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003401
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003401
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00949702
Drug: vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 960 mg b.i.d. continuous oral dosing
Study: NCT01695707
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see Arm Description
Study: NCT00044616
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00153244
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01829958
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01829958
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00059462
Drug: Interleukin-2 SA
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HAART and Bay 50-4798
Study: NCT01338740
Drug: Adalimumab and Infliximab
Normalized name: Infliximab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
Study: NCT03239392
Drug: BNZ132-1-40
Normalized name: BNZ132-1-40
DrugBank: EQ101 (DB17396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
Study: NCT02354898
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg twice daily (800mg total daily dose)
Study: NCT00035243
Drug: epothilone b
Normalized name: Epothilone B
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
Study: NCT00107341
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00107341
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00107341
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00168584
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01804400
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00413322
Drug: belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
Study: NCT00413322
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
Study: NCT01587716
Drug: GSK2339345 (Inhaled) Repeat Dose
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 microgram (proposed dose) administered 4 times a day for two consecutive days
Study: NCT01062529
Drug: Somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 h of 150 microgram infusion
Study: NCT01970020
Drug: JNJ-38518168
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
Study: NCT00343148
Drug: AVI-4126 Injection (RESTEN-NG®)
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03332225
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with anakinra
Study: NCT03332225
Drug: Recombinant human interferon-gamma
Normalized name: interferon gamma, porcine recombinant
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with recombinant human interferon-gamma
Study: NCT00454324
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
Study: NCT00454324
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)
Study: NCT00307775
Drug: oestradiol
Normalized name: Oestradiol
DrugBank: Fluoroestradiol F-18 (DB15690)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03441828
Drug: Deep Neuromuscular Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maintenance of a deep neuromuscular block by infusion of rocuronium
Study: NCT03441828
Drug: Moderate Neuromuscular Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maintenance of a moderate neuromuscular block.
Study: NCT01559584
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One monthly injections of intralesional triamcinolone acetonide
Study: NCT02643914
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01626469
Drug: Captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg Captopril
Study: NCT04477096
Drug: HS-10234
Normalized name: sodium fluoride 0.00234 MG/MG
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HS-10234
Study: NCT04477096
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine
Study: NCT02839200
Drug: ACT-541468 5 mg
Normalized name: sodium fluoride 0.5 MG/ML [ACT Fluoride Rinse]
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule for oral administration containing ACT-541468 at a strength of 5 mg
Study: NCT02839200
Drug: ACT-541468 10 mg
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule for oral administration containing ACT-541468 at a strength of 10 mg